NOAA releases 2026 fiscal year budget, looks to terminate or reduce over 50 programs/projects
According to the report, NOAA is requesting a budget of $4,515,302,000.
'The NOAA FY 2026 request will make critical investments to better enable NOAA to address current and emerging needs of the Nation. Through this budget, NOAA will help unleash American energy through initiatives supporting the marine mining market, leverage innovation in the weather and space enterprises, and enable and promote economic growth. Additional details are provided in the ensuing exhibits,' NOAA's budget proposal says.
Some programs that are to be terminated or decreased, according to the fiscal budget, are:
Decreases
The National Severe Storms Laboratory
Sustained Ocean Observations and Monitoring Reduction
Tornado Severe Storm Research / Phased Array Radar Reduction
Science and Technology Integration Decrease
Polar Weather Satellites
National Centers for Environmental Information Decrease
Product Development, Readiness and Application Decrease
Terminations
Terminate NOAA Community Project Funding/NOAA Special Projects
Termination of NOAA's National Centers for Coastal Ocean Science
Terminate Federal Support for National Estuarine Research Reserve System
Habitat Conservation and Restoration Termination
Termination of OAR's Climate Laboratories and Cooperative Institutes
Termination of OAR's Weather Laboratories and Cooperative Institutes
The FY 2026 budget eliminates all funding for climate, weather, and ocean Laboratories and Cooperative Institutes. It also does not fund Regional Climate Data and Information, ClimateCompetitive Research, the National Sea Grant College Program, Sea Grant Aquaculture Research, or the National Oceanographic Partnership Program. Of the remaining funded programs, the U.S. Weather Research Program, Tornado Severe Storm Research / Phased Array Radar, the Joint Technology Transfer Initiative, High Performance Computing Initiatives, and Research Supercomputing will be transitioned to the NWS and Ocean Exploration and Research, Integrated Ocean Acidification, and Sustained Ocean Observations and Monitoring will be transitioned to NOS. These adjustments will allow these research programs to carry out research that is more directly related to the NOAA mission.
NOAA FY 2026 budget
You can read the full NOAA 2026 Fiscal Year budget here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Illustration of TAT Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals. Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy. The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers. An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics. Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development. Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world. About Alfa Cytology Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine. Media Contact Company Name: Alfa Cytology Contact Person: Thassia C. Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Associated Press
an hour ago
- Associated Press
AI-Assisted Technique Can Measure and Track Aging Cells
NEW YORK, July 7, 2025 /PRNewswire/ -- A combination of high-resolution imaging and machine learning, also known as artificial intelligence (AI), can track cells damaged from injury, aging, or disease, and that no longer grow and reproduce normally, a new study shows. These senescent cells are known to play a key role in wound repair and aging-related diseases, such as cancer and heart disease, so tracking their progress, researchers say, could lead to a better understanding of how tissues gradually lose their ability to regenerate over time or how they fuel disease. The tool could also provide insight into therapies for reversing the damage. Led by NYU Langone Health Department of Orthopedic Surgery researchers, the study included training a computer system to help analyze animal cells damaged by increasing concentrations of chemicals over time to replicate human aging. Cells continuously confronted with environmental or biological stress are known to senesce, meaning they stop reproducing and start to release telltale molecules indicating that they have suffered injury. Publishing in the journal Nature Communications online July 7, the researchers' AI analysis revealed several measurable features connected to the cell's control center (nucleus), that, when taken together, closely tracked with the degree of senescence in the tissue or group of cells. This included signs that the nucleus had expanded, had denser centers or foci, and had become less circular and more irregular in shape. Its genetic material also stained lighter than normal with standard chemical dyes. Further testing confirmed that cells with these characteristics were indeed senescent, showing signs that they had stopped reproducing, had damaged DNA, and had densely packed enzyme-storing lysosomes. The cells also demonstrated a response to existing senolytic drugs. From their analysis, researchers created what they term a nuclear morphometric pipeline (NMP) that uses the nucleus's changed physical characteristics to produce a single senescent score to describe a range of cells. For example, groups of fully senescent cells could be compared to a cluster of healthy cells on a scale from minus 20 to plus 20. To validate the NMP score, the researchers then showed that it could accurately distinguish between healthy and diseased mouse cells from young to older mice, age 3 months to more than 2 years. Older cell clusters had significantly lower NMP scores than younger cell clusters. The researchers also tested the NMP tool on five kinds of cells in mice of different ages with injured muscle tissue as it underwent repair. The NMP was found to track closely with changing levels of senescent and nonsenescent mesenchymal stem cells, muscle stem cells, endothelial cells, and immune cells in young, adult, and geriatric mice. For example, use of the NMP was able to confirm that senescent muscle stem cells were absent in control mice that were not injured, but present in large numbers in injured mice immediately after muscle injury (when they help initiate repair), with gradual loss as the tissue regenerated. Final testing showed that the NMP could successfully distinguish between healthy and senescent cartilage cells, which were 10 times more prevalent in geriatric mice with osteoarthritis than in younger, healthy mice. Osteoarthritis is known to progressively worsen with age. 'Our study demonstrates that specific nuclear morphometrics can serve as a reliable tool for identifying and tracking senescent cells, which we believe is key to future research and understanding of tissue regeneration, aging, and progressive disease,' said study senior investigator Michael Wosczyna, PhD. Wosczyna is an assistant professor in the Department of Orthopedic Surgery at the NYU Grossman School of Medicine. Wosczyna says his team's study confirms the NMP's broad application for study of senescent cells across all ages and differing tissue types, and in a variety of diseases. He says the team plans further experiments to examine use of the NMP in human tissues, as well as combining the NMP with other biomarker tools for examining senescence and its various roles in wound repair, aging, and disease. The researchers say their ultimate goal for the NMP, for which NYU has filed a patent application, is to use it to develop treatments that prevent or reverse negative effects of senescence on human health. 'Our testing platform offers a rigorous method to more easily than before study senescent cells and to test the efficacy of therapeutics, such as senolytics, in targeting these cells in different tissues and pathologies,' said Wosczyna, who plans to make the NMP freely available to other researchers. 'Existing methods to identify senescent cells are difficult to use, making them less reliable than the nuclear morphometric pipeline, or NMP, which relies on a more commonly used stain for the nucleus,' said study co-lead investigator Sahil Mapkar, BS, Mapkar is a doctoral candidate at the NYU Tandon School of Engineering. Funding for the study was provided by National Institutes of Health grant R01AG053438 and the Department of Orthopedic Surgery at NYU Langone. Besides Wosczyna and Makpar, NYU Langone researchers involved in this study are co-lead investigators Sarah Bliss, and Edgar Perez Carbajal, and study co-investigators Sean Murray, Zhiru Li, Anna Wilson, Vikrant Piprode, Youjin Lee, Thorsten Kirsch, Katerina Petroff, and Fengyuan Liu. About NYU Langone Health NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise. Media Contact David March 212-404-3528 [email protected] STUDY LINK STUDY DOI 10.1038/s41467-025-60975-z View original content to download multimedia: SOURCE NYU Langone Health System
Associated Press
an hour ago
- Associated Press
CD BioSciences Announces Advanced Environmental Microbiology Testing Services for Environmental Protection
CD BioSciences announces advanced environmental microbiology testing services for environmental protection. CD BioSciences, a bio-sustainable solutions company, is proud to announce its environmental microbiology testing services, a step further in its commitment to eco-friendly innovations and sustainability. In its cutting-edge biotechnology facility, CD BioSciences is listening to customer needs for more sustainable and environmentally friendly practices. The company is answering with a new line of environmental microbiology testing services. This is a part of a larger goal to help improve biodiversity and ecological well-being in agriculture, industry, and urban development, and the highly customized and scientific testing services are designed for solutions that help advance eco-conscious practices and protect the natural world. The environmental microbiology testing services utilize the latest in microbiological analysis methods and techniques to track and manage microorganisms in various settings. In addition to playing a part in the overall well-being of the world, this service is critical to the health of agricultural land and growth, clean water, and pollutant-free air. Reliable and precise microbiology analysis and testing are key to ensuring thriving soil, safe and clean water supplies, and improving air quality, all a part of a sustainable environment. CD BioSciences also offers bioenvironmental microorganism products. These new products are an innovative line of environmentally friendly, non-invasive solutions that use naturally occurring microorganisms to improve and fortify the environment and help nature protect itself. These products are designed to boost the microorganisms and activity that help to improve soil, break down pollutants, and encourage the cycles of nutrients that all healthy ecosystems rely on. By using these biological products and solutions, industries and others can help meet environmental standards and targets, increase their sustainability performance, and decrease their environmental footprint. In addition to these new products, CD BioSciences also assists with material biodegradation studies and testing for industry. Biodegradation analysis measures the effect of microorganisms on materials in the environment, including their rate of decay, and helps to determine the long-term effects of these substances and processes on the environment. It's a critical service for determining material and process alternatives for companies seeking to use and produce more sustainable products and processes with less waste. In conclusion, CD BioSciences is at the forefront of improving the health of the planet, with new microbiology testing services and environmentally friendly bioenvironmental microorganism products. With an eye always on the future and a focus on the highest quality products and services possible. About CD BioSciences CD BioSciences is a leading biotechnology company based in New York, dedicated to the ideals of innovation and sustainability. The company provides a range of eco-friendly products and services to industries worldwide in the agriculture, environmental, and biochemical fields, and offers a complete package of products and solutions backed by top-notch technical support. Media Contact Company Name: CD BioSciences Contact Person: Michelle Moser Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: CD BioSciences Announces Advanced Environmental Microbiology Testing Services for Environmental Protection
